<DOC>
	<DOCNO>NCT02305784</DOCNO>
	<brief_summary>YKL-40 propose biomarker various inflammatory disease diabetes lung disease include cystic fibrosis . In cross-sectional study , unique value YKL-40 use correlate clinical , physiological , biological determinant disease severity ( like FEV1 example lung disease ) . There one longitudinal study show correlation circulating level YKL-40 decline lung function smoker sample general population . In order well understand potential role YKL-40 CF pathophysiology , determine potential role biomarker disease evolution , essential proceed clinical evaluation . The investigator propose perform observational prospective cohort study determine variation YKL-40 concentration 24 month correlate clinical evolution patient .</brief_summary>
	<brief_title>Kinetics YKL-40 Protein Serum Cystic Fibrosis Patients</brief_title>
	<detailed_description>Observational prospective cohort : The primary objective study determine variation YKL-40 concentration ( blood sputum ) 24 month correlate biological clinical condition patient . For study , patient ( FEV1 &gt; 30 % ) positive Pseudomonas past year include , B Cepacia positive patient exclude . There presently 200 patient meet inclusion criterion . The investigator choose limit study population patient Pseudomonas since likely FEV1 change clinical evolution observation period . The investigator expect high participation rate since obligation patient provide sample visit . A blood ( serum DNA ) sputum sample take regular clinic visit ( 3-4/year-no evidence exacerbation past two week ) well begin end exacerbation treat IV antibiotic . This also allow investigator determine change YKL-40 exacerbation . The patient follow period 24 month . In parallel measurement YKL-40 blood airway secretion , biological parameter monitor ( see list ) well BMI , lung function ( FEV1/FVC ) , oxygen saturation heart rate . The investigator also monitor glucose metabolism status patient ( IGT , CFRD ) number exacerbation per year well significant change microbiology status patient . A pulmonary exacerbation define acute exacerbation pulmonary symptom opinion CF physician severe enough require intravenous antibiotic . The propose sample size , show power calculation , sufficient demonstrate meaningful change YKL-40 ( initial-final ) give plausible value standard deviation difference patient .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>1. man woman ≥ 18 an . 2. documented CF diagnostic ( sweat test genotype ) . 3 . FEV1 ≥ 25 % 4 . Stable : infection last two week visit . 1 . Exacerbation respiratory symptom ou without hospitalization last two week 2 . Exacerbation treat IV antibiotic . 3 . Patients B. Cepacia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Cystic fibrosis</keyword>
	<keyword>Pulmonary exacerbation</keyword>
	<keyword>inflammation</keyword>
	<keyword>Chitinase</keyword>
	<keyword>cytokine</keyword>
	<keyword>Cystic fibrosis relate diabetes</keyword>
</DOC>